Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)

Inhibikase Therapeutics (IKT) has 2 years of Capital Expenditures data on record, last reported at $13399.0 in Q1 2025.

On a quarterly basis, Capital Expenditures changed N/A to $13399.0 in Q1 2025 year-over-year; TTM through Dec 2025 was $13399.0, a N/A change, with the full-year FY2025 number at $13399.0, changed N/A from a year prior.
Capital Expenditures reached $13399.0 in Q1 2025 per IKT's latest filing, down from $200166.0 in the prior quarter.
Over the last five years, Capital Expenditures for IKT hit a ceiling of $200166.0 in Q3 2022 and a floor of $13399.0 in Q1 2025.